Skip to main
ZVRA
ZVRA logo

ZVRA Stock Forecast & Price Target

ZVRA Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 63%
Buy 38%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Zevra Therapeutics Inc. demonstrates a robust growth trajectory with a significant increase in patient enrollment for its MIPLYFFA therapy, rising from 90 to 109 treatment requests by the end of 2024, signaling strong market demand. The company reported impressive sales of $10.1 million in the fourth quarter of 2024, significantly surpassing estimates, indicating successful initial market penetration for its ultra-rare Niemann-Pick type C treatment. Additionally, ongoing awareness campaigns among healthcare providers and a potential European filing in the second half of 2025 further support a positive outlook for sustained revenue growth into 2025.

Bears say

Zevra Therapeutics Inc. reported a significant GAAP net loss of $20.4 million, coupled with additional non-cash expenses that further strained financial performance, raising concerns about the sustainability of its operations. Challenges such as poor payer coverage, potential adverse impacts from recent competitor approvals, and emerging safety issues are expected to hinder the market performance and growth potential of its key product, Miplyffa. Furthermore, the company has a history of ongoing losses and lacks a proven pathway to profitability, posing risks to its commercial viability and investor confidence in future developments.

ZVRA has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 63% of analysts recommend a Strong Buy, 38% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Zevra Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Zevra Therapeutics Inc (ZVRA) Forecast

Analysts have given ZVRA a Strong Buy based on their latest research and market trends.

According to 8 analysts, ZVRA has a Strong Buy consensus rating as of Jul 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Zevra Therapeutics Inc (ZVRA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.